Continuum Advisory LLC Has $2.38 Million Stock Holdings in Medtronic PLC $MDT

Continuum Advisory LLC lifted its stake in Medtronic PLC (NYSE:MDT) by 56.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 24,974 shares of the medical technology company’s stock after purchasing an additional 9,048 shares during the quarter. Continuum Advisory LLC’s holdings in Medtronic were worth $2,379,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of MDT. 1248 Management LLC purchased a new stake in Medtronic during the first quarter valued at about $26,000. Delos Wealth Advisors LLC acquired a new stake in shares of Medtronic during the second quarter valued at approximately $27,000. Twin Tree Management LP acquired a new stake in shares of Medtronic during the first quarter valued at approximately $29,000. Tripletail Wealth Management LLC purchased a new stake in shares of Medtronic in the 3rd quarter valued at approximately $34,000. Finally, GFG Capital LLC acquired a new position in Medtronic in the 2nd quarter worth approximately $36,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Trading Down 0.5%

Shares of NYSE MDT opened at $96.05 on Tuesday. The business has a 50 day simple moving average of $97.54 and a 200 day simple moving average of $93.86. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $106.33. The stock has a market cap of $123.13 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 2.54 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be issued a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic’s dividend payout ratio is currently 76.55%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Citigroup boosted their target price on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Truist Financial lowered their price target on Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Robert W. Baird set a $103.00 price objective on Medtronic in a research note on Tuesday, December 16th. Barclays lifted their target price on Medtronic from $109.00 to $111.00 and gave the company an “overweight” rating in a research note on Thursday, November 20th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price target on shares of Medtronic in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.94.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).